Elastography Imaging Market Size & Forecast 2035
The global elastography imaging market was valued at USD 2.15 billion in 2025 and is projected to reach USD 4.75 billion by 2035, expanding at a CAGR of 8.26% during 2026–2035. Growth is supported by chronic liver disease surveillance, metabolic dysfunction-associated steatotic liver disease, breast and thyroid lesion assessment, broader ultrasound access, and the integration of tissue-stiffness measurement into general imaging systems.
Elastography estimates tissue stiffness by measuring deformation or the propagation of mechanically or acoustically generated shear waves. Ultrasound elastography provides real-time, accessible measurement during a standard sonographic examination. Magnetic resonance elastography maps tissue mechanical properties over a broader field and can support liver-fibrosis assessment in patients already undergoing MRI.
The addressable market includes dedicated elastography devices, premium ultrasound and MRI systems sold with elastography capability, software options, compatible transducers, upgrades and service. Market revenue should not be interpreted as the full value of every ultrasound or MRI scanner that can run an elastography application. Commercial success depends on making stiffness measurement reproducible, clinically interpretable and efficient within routine workflow.
Key Highlights
- The market is forecast to increase from USD 2.15 billion in 2025 to USD 4.75 billion in 2035 at a CAGR of 8.26%.
- Ultrasound elastography held 84% of 2025 revenue due to portability, lower cost and integration with standard abdominal and breast imaging.
- Shear-wave elastography represented 61% of technique revenue because it provides quantitative stiffness measurements and real-time visualization.
- Liver imaging accounted for 48% of application demand, supported by noninvasive fibrosis assessment and longitudinal monitoring.
- Hospitals generated 55% of market revenue, while diagnostic imaging centers held 27%.
- North America led with 38% of global revenue; Asia-Pacific is expected to grow fastest through 2035.
- Workflow automation, quality maps, automated region-of-interest selection and measurement-validity indicators are becoming central purchasing criteria.
Market Dynamics
Liver disease creates the largest clinical demand pool
Fibrosis progression changes liver stiffness before advanced complications become visible. Elastography supports risk stratification, follow-up and treatment monitoring without exposing every patient to biopsy. The growth of metabolic liver disease expands the screening and surveillance population across primary, gastroenterology and radiology settings.
Elastography does not replace all biopsies. Inflammation, cholestasis, congestion, fasting status, obesity and acquisition quality can influence measurements. Clinical pathways therefore use stiffness alongside laboratory results, conventional imaging and patient history. Vendors that support quality control and standardized reporting are better positioned for routine use.
Ultrasound integration widens access
General-imaging systems can combine B-mode anatomy, Doppler, contrast-enhanced ultrasound, fat quantification and elastography during one examination. GE HealthCare’s LOGIQ E10 offers two-dimensional shear-wave elastography with a quality map, while Philips combines real-time shear-wave measurement with advanced transducers and navigation. This multi-parameter approach increases the value of the complete ultrasound platform.
Portable and compact systems extend access beyond tertiary hospitals, but image quality and operator training remain important. Point-of-care adoption will depend on simplified protocols and reliable quality indicators rather than portability alone.
Automation improves reproducibility
Manual region selection and frame choice contribute to operator variability. Philips Auto ElastQ assists frame selection and region-of-interest placement for liver assessment. Quality maps and confidence indicators from other vendors help identify unstable measurements. Automated tools can shorten examinations and make results more comparable across users.
Artificial intelligence may support acquisition guidance, outlier rejection and standardized reporting. Clinical responsibility still remains with trained professionals, and automated outputs require validation across body habitus, disease stage and scanner configuration.
MR elastography provides broader coverage but faces capacity constraints
MR elastography can estimate stiffness over a large portion of the liver and may be added to 1.5T or 3T examinations. It is useful when ultrasound access is limited by anatomy or obesity and when MRI already forms part of the clinical pathway. The technique requires hardware or external vibration equipment, specialized sequences, processing and scanner time.
MRI cost, availability and scheduling restrict volume. MRE is therefore a complementary premium modality rather than a direct replacement for ultrasound elastography. Partnerships between elastography specialists and MRI manufacturers help integrate acquisition and processing into standard platforms.
Reimbursement and protocol variation restrain adoption
Hospitals require evidence that elastography changes management, reduces biopsy use or improves follow-up efficiency. Payment policies differ by country and care setting. Where reimbursement is unclear, the feature may be used without generating separate revenue, weakening the equipment upgrade case.
Cutoff values can vary with disease cause, technique, vendor and protocol. Results reported in meters per second or kilopascals are not always interchangeable. Standardization, education and longitudinal use on a consistent platform are therefore important.
Market Segmentation
By Modality
Ultrasound elastography accounted for 84% of 2025 revenue. Its lead reflects lower cost, real-time acquisition, portability and integration into abdominal, breast, thyroid and musculoskeletal examinations. Magnetic resonance elastography held 16%, supported by broad tissue coverage, quantitative mapping and use in advanced liver-imaging pathways.
By Technique
Shear-wave elastography generated 61% of 2025 revenue. This category includes point shear-wave and two-dimensional shear-wave methods that provide quantitative tissue-stiffness data. Strain elastography held 22%, with use in breast, thyroid, prostate and musculoskeletal imaging. Transient elastography represented 11%, focused mainly on dedicated liver assessment. MR elastography and other specialized methods accounted for 6% within this technique view.
By System Mode
On-platform elastography integrated into cart-based ultrasound or MRI systems represented 69% of 2025 revenue. Portable and compact systems held 21%, while dedicated liver elastography devices accounted for 10%. Portable growth is supported by outreach and decentralized assessment, but integrated platforms remain dominant because they combine anatomical imaging with stiffness measurement.
By Offering
Imaging systems and hardware generated 62% of 2025 revenue. Elastography software licenses and upgrades accounted for 21%. Transducers, vibration devices and accessories held 10%, while service, training and other offerings represented 7%. Software and upgrade revenue is expected to grow as hospitals add elastography to compatible installed systems.
By Application
Liver imaging accounted for 48% of 2025 revenue. Breast imaging held 16%, supported by lesion characterization alongside B-mode and Doppler assessment. Thyroid applications represented 9%, while musculoskeletal and orthopedic imaging accounted for 8%. Prostate and urology held 6%, cardiovascular and vascular applications 5%, and gynecology, transplant, research and other uses contributed 8%.
By End User
Hospitals generated 55% of 2025 market revenue due to their installed ultrasound and MRI base and access to complex liver and oncology cases. Diagnostic imaging centers held 27%. Specialty clinics, including gastroenterology and hepatology practices, represented 10%. Academic institutes, ambulatory centers and other users contributed 8%.
By Clinical Workflow
Diagnosis and disease staging accounted for 57% of 2025 revenue. Treatment monitoring and longitudinal surveillance held 25%. Biopsy targeting and interventional guidance represented 8%, while research, drug development and other workflows contributed 10%.
Regional and Country-Level Analysis
North America
North America held 38% of global revenue in 2025. The United States represented 34% of the world market and Canada 4%. The region benefits from a large imaging installed base, high metabolic liver-disease burden and early adoption of premium ultrasound and MRI technology. U.S. demand is strongest where elastography is embedded in liver, oncology and women’s-imaging pathways. Payment variation and protocol standardization remain barriers outside major centers.
Europe
Europe accounted for 29% of 2025 revenue. Germany held 6% of the global market, the United Kingdom 4.5%, France 4%, Italy 3.5%, Spain 2.5% and the rest of Europe 8.5%. Liver-disease pathways, public imaging systems and clinical research support adoption. Germany and France have strong hospital demand, while Southern Europe has significant liver-disease assessment needs. Public procurement can favor upgrades to existing platforms when capital for new scanners is limited.
Asia-Pacific
Asia-Pacific generated 24% of global revenue and is expected to grow fastest. China represented 8% of global demand, Japan 5%, India 3.5%, South Korea 2.5%, Australia 2% and the rest of the region 3%. China combines large patient volume with expanding ultrasound access. Japan has a mature imaging market and strong liver surveillance. India offers growth through decentralized ultrasound but faces reimbursement, training and equipment-budget constraints. Compact systems and simplified protocols can improve access across the region.
Competitive Landscape
Competition is led by global ultrasound and MRI manufacturers, supplemented by dedicated elastography specialists. Large imaging companies bundle elastography with premium platforms, transducers, contrast imaging and workflow software. Specialists compete through focused liver assessment, vibration hardware, processing algorithms and partnerships.
Differentiation centers on reproducibility, penetration in difficult patients, measurement stability, quality indicators, protocol breadth and reporting. Vendor lock-in can arise because cutoff values and longitudinal results may depend on technique and platform. Training and clinical education are therefore important commercial assets.
GE HealthCare
GE HealthCare offers elastography across LOGIQ ultrasound platforms, including strain and two-dimensional shear-wave techniques. LOGIQ E10 combines quality mapping with liver fat quantification, contrast imaging and workflow tools. The company’s strength lies in its broad imaging installed base, transducer portfolio and service network. Integration of stiffness and fat measurements positions the platform for metabolic liver-disease assessment.
Koninklijke Philips N.V.
Philips provides ElastPQ, ElastQ Imaging and Auto ElastQ across EPIQ and Affiniti systems. Its liver workflow combines shear-wave elastography, contrast-enhanced ultrasound, advanced transducers and image fusion. Auto ElastQ targets measurement consistency by assisting frame and ROI selection. Philips competes through integrated clinical workflows and a large premium-ultrasound installed base.
Siemens Healthineers AG
Siemens Healthineers offers ultrasound elastography on ACUSON systems and MR elastography on MRI platforms. Its cross-modality portfolio supports liver, oncology and other tissue-stiffness applications. The company emphasizes clinical education, protocol integration and advanced imaging infrastructure. MRE capability gives Siemens a differentiated position in centers using both ultrasound and MRI for liver assessment.
Canon Medical Systems Corporation
Canon Medical offers ultrasound elastography within its diagnostic-imaging portfolio and has worked with Resoundant to integrate MR elastography into MRI platforms. Its strategy links tissue-stiffness measurement with conventional imaging and advanced MRI. Canon’s global imaging footprint and hospital relationships support multi-modality adoption, while partnerships provide specialized elastography technology.
Recent Industry Developments
- GE HealthCare expanded the LOGIQ E10 platform with two-dimensional shear-wave elastography, quality mapping and ultrasound-guided fat-fraction tools. The combination supports multi-parameter liver assessment in one examination.
- Philips introduced Auto ElastQ on EPIQ Elite and Affiniti platforms to assist liver-elastography frame selection and region-of-interest placement. The software targets precision, reproducibility and workflow consistency.
- Philips continues to combine shear-wave elastography with contrast-enhanced ultrasound, advanced transducers and image fusion. This positions elastography within a broader liver-imaging pathway rather than as an isolated measurement.
- Siemens Healthineers supports point and two-dimensional shear-wave methods across ACUSON platforms and MR elastography on 1.5T and 3T MRI systems. Its cross-modality portfolio enables clinical pathways spanning ultrasound and MRI.
- GE HealthCare’s breast-imaging workflow combines strain and two-dimensional shear-wave elastography with conventional ultrasound and microvascular imaging. This expands tissue-stiffness assessment beyond liver disease.
- MRI manufacturers continue partnerships with elastography technology providers to integrate sequences and processing into standard scanner platforms. These arrangements reduce the technical barrier to adding MRE within an existing examination.
- Elastography vendors are increasing measurement-quality maps, automated ROI tools and protocol education. The trend addresses operator dependence, which remains one of the main barriers to routine and longitudinal use.
